Dr Lin on the Selection of Systemic Therapy in HER2+ Breast Cancer With Brain Metastases
Nancy U. Lin, MD, discusses selecting between systemic vs local therapy for patients with HER2-positive breast cancer displaying central nervous system metastases.
Dr. Lin on the Advantage of Elacestrant in ESR1-Mutated Breast Cancer
Nancy U. Lin, MD, discusses the advantage of the oral selective estrogen receptor degrader, elacestrant, in ESR1-mutated breast cancers.
Dr. Lin on Treatment Challenges in HER2+ Breast Cancer and Brain Metastases
Nancy U. Lin, MD, discusses the challenges faced in the treatment of patients with HER2-positive breast cancer and brain metastases.
Dr. Lin on Developing Systemic Therapies for Patients with Brain Metastases in HER2+ Breast Cancer
Nancy U. Lin, MD, discusses the development of systemic therapies for the treatment of patients with metastatic HER2-positive breast cancer and brain metastases.
Dr. Lin on Updated Findings of HER2CLIMB Study in HER2+ Breast Cancer Brain Mets
Nancy U. Lin, MD, discusses updated findings from the phase 2 HER2CLIMB study in patients with HER2-positive metastatic breast cancer with brain metastases.
Dr. Lin on CNS Activity With HER2-Directed TKIs in HER2+ Breast Cancer
Nancy U. Lin, MD, discusses central nervous system activity with HER2-directed TKIs in HER2-positive breast cancer.
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant
Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies
2 Commerce Drive Cranbury, NJ 08512